alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
A93A1303.

#### ICI AMERICAS, INC. v. BANKS et al.

(472 SE2d 570)

Decided June 7, 1996.

*Rogers & Hardin, Brett A. Rogers, Phillip S. McKinney, Susan D. Burnell, Schweber, Izenson & Anderson, Barry L. Anderson, Hagler, Hyles, Adams & McKenna, M. Stephen Hyles,*for appellant.

Andrews, Judge.

In *Banks v. ICI Americas,*264 Ga. 732 (450 SE2d 671) (1994), our decision in *ICI Americas v. Banks,*211 Ga. App. 523 (440 SE2d 38) (1993), reversing the trial court’s judgment in favor of the plaintiffs, Banks et al., was affirmed in part, reversed in part, and remanded to this Court with directions “that a new trial be granted [to the plaintiffs on their defective design claim] unless a new trial is precluded by the Court of Appeals’ resolution of the remaining enumerations of error [raised by ICI].” *Banks,*264 Ga. at 737. On remand in *ICI Americas v. Banks,*218 Ga. App. 237 (460 SE2d 797)

(1995) , we addressed ICI’s remaining enumerations of error and concluded that none of those enumerations precluded a new trial. We also concluded that, in a new trial under the new risk-utility analysis adopted and retroactively applied by the Supreme Court in *Banks,*supra, 264 Ga. 732, punitive damages could not be awarded against ICI if the jury found it failed to comply with the new retroactively applied rule. In *Banks v. ICI Americas,*266 Ga. 607 (469 SE2d 171) (1996) , the Supreme Court held that “the Court of Appeals erred by holding that plaintiffs are barred upon retrial from seeking punitive damages and its opinion is accordingly reversed.”

Pursuant to the above cited decisions of the Supreme Court, our decision in *Banks,*supra, 218 Ga. App. 237 is vacated, and the judgment of the Supreme Court is made the judgment of this Court. Accordingly, as to the plaintiffs’ claims based on inadequate or inaccurate product labeling, the judgment of the trial court is reversed. *Banks,*supra, 211 Ga. App. 523, 527, aff’d, 264 Ga. 732, 737. As to the plaintiffs’ design defect claims, the trial court’s judgment is vacated, and the case is remanded for a new trial under the new test for design defect claims set forth by the Supreme Court in *Banks,*supra, 264 Ga. 732.

*Judgment reversed in part, vacated in part, and case remanded with directions.*

*Beasley, C. J., McMurray, R J, Birdsong, P. J, Pope, P. J., Johnson, Blackburn, Smith and Ruffin, JJ, concur.*

*666*Webb, Carlock, Copeland, Sender & Stair, Wade K. Copeland, Doffermyre, Shields, Canfield & Knowles, Robert E. Shields, Denney, Pease, Allison, Kirk & Lomax, Ray L. Allison, Richard A. Childs,*for appellees.
9122 Federal Register / Vol. 73, No. 33 / Tuesday, February 19, 2008 / Notices 

Management and Budget, Paperwork 

Reduction Project, Fax: 202–395–6974, 

Attn: Desk Officer for the 

Administration for Children and 

Families. 

Dated: February 11, 2008. 

Janean Chambers, 

Reports Clearance Officer. 

[FR Doc. 08–697 Filed 2–15–08; 8:45 am] 

BILLING CODE 4184–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[FDA No. 225–08–8002] 

Memorandum of Understanding 

Between the Division of Select Agents 

and Toxins Center for Disease Control 

and Prevention and the Food and Drug 

Administration 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is providing 

notice of a memorandum of 

understanding (MOU) between FDA and 

the Division of Select Agents and 

Toxins (DSAT) of the Centers for 

Disease Control and Prevention (CDC). 

The purpose of this MOU is to establish 

a procedure to allow CDC/DSAT to 

confirm that FDA has accepted or 

approved, under the authority of the 

Federal Food, Drug, and Cosmetic Act 

(21 U.S.C. 301 et seq), an Investigational 

New Drug application (IND), a request 

to establish an Investigational New 

Animal Drug file (INAD), or an 

Investigational Device Exemption 

application (IDE) for a clinical trial 

involving the use of an investigational 

product that is, bears, or contains a 

select agent or toxin. 

DATES: The agreement became effective 

January 25, 2008. 

FOR FURTHER INFORMATION CONTACT: 

Jarilyn Dupont, Director of Regulatory 

Policy, Office of Policy and Planning 

(HF–11), Food and Drug 

Administration, 5600 Fishers Lane, 

Rockville, MD 20857, 301–827–5906. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 20.108(c), 

which states that all written agreements 

and MOUs between FDA and others 

shall be published in the Federal 

Register, the agency is publishing notice 

of this MOU. 

Dated: February 8, 2008. 

Jeffrey Shuren, 

Assistant Commissioner for Policy. 

BILLING CODE 4160–01–S 

mstockstill on PROD1PC66 with NOTICES

Federal Register / Vol. 73, No. 33 / Tuesday, February 19, 2008 / Notices 9123 


mstockstill on PROD1PC66 with NOTICESEN19FE08.000</GPH>
9124 Federal Register / Vol. 73, No. 33 / Tuesday, February 19, 2008 / Notices 


mstockstill on PROD1PC66 with NOTICESEN19FE08.001</GPH>
Federal Register / Vol. 73, No. 33 / Tuesday, February 19, 2008 / Notices 9125 


mstockstill on PROD1PC66 with NOTICESEN19FE08.002</GPH>
9126 Federal Register / Vol. 73, No. 33 / Tuesday, February 19, 2008 / Notices 

[FR Doc. 08–686 Filed 2–15–08; 8:45 am] 

BILLING CODE 4160–01–C 


mstockstill on PROD1PC66 with NOTICESEN19FE08.003</GPH>
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Commodity Futures Trading Commission

# Time and Date:

10 a.m., Friday, March 7, 2008.

# Place:

1155 21st St., NW., Washington, DC, 9th Floor Commission Conference Room.

# Status:

Closed.

# Matters to be Considered:

Clearing and Intermediary Oversight Matters.

# Contact Person For More Information:

Sauntia S. Warfield, 202-418-5084.

David A. Stawick,

Secretary of the Commission.

[FR Doc. 08-897 Filed 2-26-08; 1:06 pm]

BILLING CODE 6351-01-P
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Homeland Security

###### U.S. Customs and Border Protection

# AGENCY:

U.S. Customs and Border Protection, Department of Homeland Security.

# ACTION:

Notice of approval of Altol Petroleum Product Service, as a commercial gauger. 

# SUMMARY:

                        Notice is hereby given that, pursuant to 19 CFR 151.13, Altol Petroleum Product Service, Road 127 Km. 13.5 Bo. Magas Arriba, Guayanilla, PR 00656, has been approved to gauge petroleum, petroleum products, organic chemicals and vegetable oils for customs purposes, in accordance with the provisions of 19 CFR 151.13. Anyone wishing to employ this entity to conduct gauger services should request and receive written assurances from the entity that it is approved by the U.S. Customs and Border Protection to conduct the specific gauger service required. Alternatively, inquiries regarding the specific gauger service this entity is approved to perform may be directed to the U.S. Customs and Border Protection by calling (202) 344-1060. The inquiry may also be sent to                         *cbp.labhq@dhs.gov*. Please reference the Web site listed below for a complete listing of CBP approved gaugers and accredited laboratories.                         *http://cbp.gov/​xp/​cgov/​import/​operations_​support/​labs_​scientific_​svcs/​commercial_​gaugers/​.*

# DATES:

The approval of Altol Petroleum Product Service, as commercial gauger became effective on September 28, 2007. The next triennial inspection date will be scheduled for September 2010.

# FOR FURTHER INFORMATION CONTACT:

Commercial Gauger Laboratory Program Manager, Laboratories and Scientific Services, U.S. Customs and Border Protection, 1300 Pennsylvania Avenue, NW., Suite 1500N, Washington, DC 20229, 202-344-1060.

Dated: January 31, 2008.

Ira S. Reese,

Executive Director, Laboratories and Scientific Services.

[FR Doc. 08-651 Filed 2-13-08; 8:45 am]

BILLING CODE 9111-14-M
Executive Order 13461

# Providing an Order of Succession Within the Department of Health and Human Services

                        By the authority vested in me as President by the Constitution and the laws of the United States of America, including the Federal Vacancies Reform Act of 1998, 5 U.S.C. 3345*et seq*., it is hereby ordered that:                    

**Section 1.**                         Subject to the provisions of section 3 of this order, the officers named in section 2, in the order listed, shall act as and perform the functions and duties of the Office of the Secretary of Health and Human Services (Secretary), if they are eligible to act as Secretary under the provisions of the Federal Vacancies Reform Act of 1998, during any period in which the Secretary has died, resigned, or become otherwise unable to perform the functions and duties of the office of Secretary.                    

**Sec. 2.***Order of Succession*.                     

(a) Deputy Secretary of Health and Human Services; 

(b) General Counsel of the Department of Health and Human Services; 

(c) Assistant Secretary (Resources and Technology); 

(d) Assistant Secretary (Planning and Evaluation); 

(e) Administrator of the Centers for Medicare and Medicaid Services; 

(f) Commissioner of Food and Drugs; 

(g) Director of the National Institutes of Health; 

(h) Assistant Secretary for Family Support; 

(i) Other Assistant Secretaries of the Department of Health and Human Services appointed by the President, in the order in which they shall have taken the oath of office as such; 

(j) Director, Centers for Disease Control and Prevention; and 

(k) Director, Region 4.

**Sec. 3.***Exceptions*.                     

(a) No individual who is serving in an office listed in section 2 of this order in an acting capacity, by virtue of so serving, shall act as Secretary pursuant to this order. 

(b) Notwithstanding the provisions of this order, the President retains discretion, consistent with the Federal Vacancies Reform Act of 1998, to depart from this order in designating an acting Secretary.

**Sec. 4.***Revocation*. Executive Order 13250 of December 28, 2001 (Providing An Order of Succession Within the Department of Health and Human Services), and the President's memorandum of March 19, 2002 (Designation of Officers of the Department of Health and Human Services), are hereby revoked.                    

[FR Doc. 08-797

Billing code 3195-01-P
Summary – ORAUT-OTIB-0015, Rev. 00 1 SC&A – January 20, 2011

Overview of

BAYESIAN METHODS FOR ESTIMATION OF UNMONITORED Y-12 EXTERNAL 

PENETRATING DOSES WITH A TIME-DEPENDENT LOGNORMAL MODEL

(ORAUT-OTIB-0015, Rev. 0) 

Workers at many Department of Energy and Atomic Weapons Employer facilities have the 

potential to receive an external radiation dose due to exposure to radioactive material. The 

Technical Information Bulletin (TIB), Bayesian Methods for Estimation of Unmonitored Y-12 

External Penetrating Doses With a Time-dependent Lognormal Model (ORAUT-OTIB-0015), 

provides guidance on the use of a method, based on the mathematical technique of Bayesian 

analysis, for assigning doses at the Y-12 Site to personnel who have limited or no monitoring 

data. This assignment of dose is based on data appropriately taken from records of other workers 

with similar work history on the same site. 

 

SUMMARY OF FINDINGS RESULTING FROM THE TECHNICAL REVIEW

The technical contractor for the Advisory Board on Radiation and Worker Health (the Board) 

reviewed the TIB and produced the four findings summarized below: 

Finding #1: Certain variables are not defined. 

Finding #2: The method to determine potential radiation dose uses a factor called Limit of 

Detection (LOD) related to the sensitivity of radiation monitoring. The Limit of Detection 

assumed by this procedure is too low and therefore not claimant favorable. 

Finding #3: The TIB makes use of 40 calendar quarters of coworker exposure data for 1956–

1965, but another technical document indicates that only the data from 37 quarters are reliable.

Finding #4: The procedure does not contain any prescriptive information. Additionally, it 

contains a level of detail related to the theory underlying the methodology that is far more than 

reasonable, needed, or desired for dose reconstruction. 

RESOLUTION OF FINDINGS

The National Institute for Occupational Safety and Health (NIOSH) decided to no longer use 

Bayesian methods for dose reconstructions and cancelled the TIB. Therefore, all findings with 

respect to this OTIB are no longer relevant.
Exhibit 32.2








CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350




AS ADOPTED PURSUANT TO




SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002







In connection with the quarterly report on Form 10-Q of FSP 303 East Wacker Drive Corp. (the “Company”) for the period ended September 30, 2009 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Barbara J. Fournier, Chief Operating
Officer and principal financial officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that, to her knowledge:





(1)
the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and





(2)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.











Date:  November 6, 2009
/s/ Barbara J. Fournier
Barbara J. Fournier
Chief Operating Officer
(Principal Financial Officer)
[Federal Register Volume 73, Number 30 (Wednesday, February 13, 2008)]
[Notices]
[Page 8319]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 08-625]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES


Office of the National Coordinator for Health Information 
Technology; American Health Information Community Consumer Empowerment 
Workgroup Meeting

ACTION: Announcement of meeting.

-----------------------------------------------------------------------

SUMMARY: This notice announces the 24th meeting of the American Health 
Information Community Consumer Empowerment Workgroup in accordance with 
the Federal Advisory Committee Act (Pub. L. No. 92-463, 5 U.S.C., 
App.).

DATES: March 18, 2008, from 1 p.m. to 4 p.m. [Eastern].

ADDRESSES: Mary C. Switzer Building (330 C Street, SW., Washington, DC 
20201), Conference Room 4090. Please bring photo ID for entry to a 
Federal building.

FOR FURTHER INFORMATION CONTACT: http://www.hhs.gov/healthit/ahic/consumer/.

SUPPLEMENTARY INFORMATION: The Workgroup will continue its discussion 
on how to encourage the widespread adoption of a personal health record 
that is easy-to-use, portable, longitudinal, affordable, and consumer-
centered.
    The meeting will be available via Web cast. For additional 
information, go to: http://www.hhs.gov/healthit/ahic/consumer/ce_instruct.html.

    Dated: January 30, 2008.
Judith Sparrow,
Director, American Health Information Community, Office of Programs and 
Coordination, Office of the National Coordinator for Health Information 
Technology.
[FR Doc. 08-625 Filed 2-12-08; 8:45 am]
BILLING CODE 4150-45-M
EXHIBIT 10.30


 



EXTENSION OF TIME FOR


CONVERTIBLE SECURED PROMISSORY NOTE DATED JULY 16, 2015


 




Whereas, this Extension of Time for Convertible Secured Promissory Note dated July 16, 2015 (this “Extension”) between Hydrocarb Energy Corporation, (the “Company”) that executed a Convertible Secured Promissory Note (the “Promissory Note” as a copy attached hereto as “Exhibit A”) in favor of Duma Holdings, LLC, a Texas limited liability company (the “Holder”) that was effective as of July 16, 2015 and the fact that such Promissory Note carries the following basic terms among others:







	
Face Value:

	
$350,000


	
Annual Interest Rate:

	
15%


	
Accrued interest through 11/30/2015:

	
$19,705


	
Original Maturity Date:

	
11/30/2015    and,





 


Whereas, the Company and Holder collectively herein will be referred to individually as a “Party” and collectively as the “Parties”; and







Whereas it is the mutual desire of the Parties to extend the maturity date of The Promissory Note for up to a total of up to six months from the original maturity date, or to May 31, 2016; and







So Now Therefore the parties agree as evidenced by the signatures hereunder that:



		1.	FIRST EXTENSION. All the terms other than the Maturity Date of November 30, 2015 which shall now be extended to February 29, 2016, shall remain the same.   The consideration for the first extension to be paid upon signature of this Extension shall be:






		a.	Cash payment of Accrued Interest of $19,705 through November 30, 2015.






		b.	Cash payment of a $3,500 extension fee.






		c.	Upon the signatures hereunder and payments made as specified above, the effective date of the FIRST EXTENSION shall be December 1, 2015.






		2.	SECOND EXTENSION. An option of another extension extending the maturity date from February 29, 2016 to May 31, 2016 will be available at the option of the Company by:






		a.	Notice to extend 10 days before maturity of FIRST EXTENSION.






		b.	Cash payment by the FIRST EXTENSION maturity date of the following:






		i.	Accrued Interest (using 15% APR) for the period of December 1, 2015 through February 29, 2016.






		ii.	Extension fee of $3,500.










All terms shall remain the same as the Promissory Note including but not limited to:



		1)	The same interest rate (15%) will be maintained,






		2)	The same stock convertible right and terms to be retained






		3)	The same real estate collateral\lien, and personal guarantees to be retained










Agreed:







	
HYDROCARB ENERGY CORPORATION

	 	
DUMA HOLDINGS, LLC

	 
	  	 	  	 
	/s/ Kent P. Watts	 	/s/ Brent Sagissor	 



	
Name: Kent P. Watts

	 	
Name:

	Brent Sagissor	 
	
Title:   Chief Executive Officer

	 	
Title: Manager

	 
	 	 	 	 
	
Agreed:

	 	 	 
	
/s/ Michael E. Watts

	 	 	 
	
Michael E. Watts

	 	 	 
	 	 	 	 
	
/s/ Kent P. Watts

	 	 	 
	
Kent P. Watts
IN THE SUPREME COURT OF THE STATE OF MONTANA No. DA 20 - 0041 STATE OF MONTANA,

Plaintiff and Appellee, v. ERIC D. YEATON,

Defendant and Appellant
.

ORDER Upon consideration of Appellant’s motion for extension of time, and good cause appearing, IT IS HEREBY ORDERED that Appellant is granted an extension of time to and including May 22 , 20 20 , within which to prepare, file, and serve Appellant’s opening brief on appeal.

Electronically signed by: Mike McGrath Chief Justice, Montana Supreme Court

April 15 2020

04/15/2020

Case Number: DA 20-0041
```

[Congressional Bills 115th Congress]
[From the U.S. Government Publishing Office]
[H.R. 6050 Introduced in House (IH)]

<DOC>

115th CONGRESS
  2d Session
                                H. R. 6050

To allow all individuals purchasing health insurance in the individual 
       market the option to purchase a lower premium copper plan.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                              June 8, 2018

 Mr. Burgess introduced the following bill; which was referred to the 
                    Committee on Energy and Commerce

_______________________________________________________________________

                                 A BILL

 
To allow all individuals purchasing health insurance in the individual 
       market the option to purchase a lower premium copper plan.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Increasing Access to Care Act''.

SEC. 2. ALLOWING ALL INDIVIDUALS PURCHASING HEALTH INSURANCE IN THE 
              INDIVIDUAL MARKET THE OPTION TO PURCHASE A LOWER PREMIUM 
              COPPER PLAN.

    (a) In General.--Section 1302(e) of the Patient Protection and 
Affordable Care Act (42 U.S.C. 18022(e)) is amended--
            (1) in paragraph (1)--
                    (A) by redesignating clauses (i) and (ii) of 
                subparagraph (B) as subparagraphs (A) and (B), 
                respectively, and adjusting the margins accordingly;
                    (B) by striking ``plan year if--'' and all that 
                follows through ``the plan provides--'' and inserting 
                ``plan year if the plan provides--''; and
                    (C) in subparagraph (A), as so redesignated, by 
                striking ``clause (ii)'' and inserting ``subparagraph 
                (B)'';
            (2) by striking paragraph (2); and
            (3) by redesignating paragraph (3) as paragraph (2).
    (b) Risk Pools.--Section 1312(c)(1) of the Patient Protection and 
Affordable Care Act (42 U.S.C. 18032(c)(1)) is amended by inserting 
``and including enrollees in catastrophic plans described in section 
1302(e)'' after ``Exchange''.
    (c) Conforming Amendment.--Section 1312(d)(3)(C) of the Patient 
Protection and Affordable Care Act (42 U.S.C. 18032(d)(3)(C)) is 
amended by striking ``, except that in the case of a catastrophic plan 
described in section 1302(e), a qualified individual may enroll in the 
plan only if the individual is eligible to enroll in the plan under 
section 1302(e)(2)''.
    (d) Effective Date.--The amendments made by this section shall 
apply with respect to plan years beginning on or after January 1, 2019.
                                 <all>
```